NEW YORK, NY / ACCESSWIRE / June 18, 2020 / National Grid Plc (NYSE:NGG) will be discussing their earnings results in their 2020 Second Half Earnings call to be held on June 18, 2020 at 9:15 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/64488

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 594339

TORONTO, ONTARIO / ACCESSWIRE / June 18, 2020 / Talisker Resources Ltd. ("Talisker" or the "Company") (CSE:TSK) (OTCQB:TSKFF) is pleased to announce that the Company has initiated its 2020 greenfields exploration program at its wholly-owned Spences Bridge and Remington Gold Projects.

A team of 20 geologists will implement the program that will focus on the completion of the regional stream sediment geochemical program initiated in 2019 (Phase 1). In addition, the team will conduct a systematic evaluation of the over 100 new geochemical anomalies generated from the 2019 exploration program. This Phase 2 program will consist of 6,500 soil samples planned to cover three large prospect areas defined by multi-element, multi-basin anomalies. In addition, the Company plans on completing permitting for a planned drill program at the Golden Hornet and Dora Gold Projects late in the 2020 field season. Drilling at the Dora Gold Project will target low sulphidation epithermal veining associated to contact breccias on the margins of hyperbyssal felsic intrusives.

Historical work on the Golden Hornet zone identified of a NW trending sheet vein system with trench sample intercepts of 27 g/t Au over 2 meters; 22.1 g/t Au over 5.2 meters; 4.17 g/t Au over 14 meters; and 1.32 g/t Au over 17 meters, among others. Confirmation grab sampling of the veins returned values of 26.1g/t and 12g/t gold. The Company notes that these selected samples are not necessarily representative of the mineralization hosted on the Golden Hornet property and limited drilling has been completed.

Terry Harbort, President & CEO of Talisker commented, "We are very excited to have our team back in the field following the postponement of work due to the Covid-19 crisis. We look to continue the success of our aggressive 2019 program and advancing our extensive pipeline to drill stage."

The Company is also pleased to announce that it has entered into a definitive purchase agreement with an arm's length vendor to purchase the SC Property (166.24 hectares) which is contiguous to the Dora Gold Project. Talisker plans to include the SC Property in the Dora Gold drill permit application. The SC Property contains a large gold in soil anomaly directly above a mapped rhyolitic body hosted within the Spences Bridge Volcanics. The historical trenches exposed strongly silicified rhyolite, hosting stockwork banded low-sulphidation veins and anomalous values up to 1.7 g/t Au. The SC property extends the geochemical anomaly present at Dora which includes historical rock samples as high as 7.68 g/t Au and represents an additional target within the Dora project. Under the terms of the purchase agreement, Talisker has agreed to pay $30,000 cash and will issue 150,000 shares to the vendor along with a 1% NSR in return for 100% ownership of the SC Property. The NSR can be purchased by Talisker for $500,000. The common shares issued will be subject to a four month hold period pursuant to applicable securities laws.

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration of gold projects in British Columbia, Canada. Talisker's projects include the Bralorne Gold Complex, an advanced stage project with significant exploration potential from a historical high-grade producing gold mine as well as its Spences Bridge Project where the Company holds ~85% of the emerging Spences Bridge Gold Belt and several other early stage Greenfields projects. With its properties comprising 291,339 hectares over 321 claims, six leases and 181 crown grant claims, Talisker is a dominant exploration player in the south-central British Columbia. The Company is well funded to advance its aggressive systematic exploration program at its projects.

For further information please contact:

Terry Harbort, Chief Executive Officer or
terry.harbort@taliskerresources.com
+1 416 361 2808

Carrie Howes, Director, Investor Relations
carrie.howes@taliskerresources.com
+1 416 837 0075

Qualified Person

The technical information contained in this news release has been reviewed and approved by Luis Arteaga, M.Sc. P.Geo., Talisker's Exploration Manager, who is a "qualified person" within the meaning of National Instrument 43-101, Standards of Disclosure for Mineral Projects.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Caution Regarding Forward Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Talisker's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to, among other things, the operations of the Company and the timing which could be affected by the current global COVID-19 pandemic. Those assumptions and factors are based on information currently available to Talisker. Although such statements are based on reasonable assumptions of Talisker's management, there can be no assurance that any conclusions or forecasts will prove to be accurate.

While Talisker considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect. Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined, risks relating to variations in grade or recovery rates, risks relating to changes in mineral prices and the worldwide demand for and supply of minerals, risks related to increased competition and current global financial conditions and the COVID-19 pandemic, access and supply risks, reliance on key personnel, operational risks, and regulatory risks, including risks relating to the acquisition of the necessary licenses and permits, financing, capitalization and liquidity risks.

The forward-looking information contained in this release is made as of the date hereof, and Talisker is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

SOURCE: Talisker Resources Ltd.

ReleaseID: 594315

TORONTO, ON / ACCESSWIRE / June 18, 2020 / Anaconda Mining Inc. ("Anaconda" or the "Company") (TSX:ANX)(OTCQX:ANXGF) is pleased to announce the results of a 2,305-metre infill drill program at the Argyle Deposit ("Argyle Infill Program"), located approximately 4.5 kilometres from the Company's operating Pine Cove Mill and tailings facility at the Point Rousse Project in Newfoundland (Exhibit A). The purpose of the Argyle Infill Program, comprised of both percussion and diamond drilling, was to better define and upgrade all shallow portions of the deposit to the Indicated Resource category in anticipation of mine development in the second half of 2020. Twenty-four diamond drill holes (AE-20-134 to 157) were completed totaling 1,448.4 metres and 61 percussion holes (AEP-20-26 to 86) were completed totaling 856.3 metres (Exhibit B).

Highlights from the Argyle Infill Program include:

5.26 g/t gold over 4.0 metres (19.5 to 23.5 metres) in diamond drill hole AE-20-140;
4.56 g/t gold over 4.5 metres (37.0 to 41.5 metres); including 24.70 g/t gold over 0.5 metres in diamond drill hole AE-20-138;
2.16 g/t gold over 8.5 metres (15.0 to 23.5 metres) in diamond drill hole AE-20-143;
6.62 g/t gold over 4.57 metres (10.97 to 15.54 metres) in percussion hole AEP-20-50; and
4.48 g/t gold over 9.14 metres (7.32 to 16.46 metres); including 16.61 g/t gold over 0.91 metres in percussion hole AEP-20-78.

Selected intersections from the Argyle Infill Program are shown in Tables 1 and 2 below.

"With the final Argyle drill results in hand and with work progressing on Mineral Resources and development plans across Point Rousse, we anticipate a new Mineral Resource and Reserve statement for the Point Rousse Project in the next quarter. This will include over 17,000 metres of drilling completed since the last resource update at Point Rousse and will include an additional 7,940 metres of drilling at Argyle alone. As this work progresses, we are also actively drilling near the Pine Cove Mill to advance other areas for near-term development, all while we continue to generate significant cashflow from our Point Rousse operations. In the current gold-price environment, Anaconda is well positioned to leverage existing permitted infrastructure to quickly and efficiently move gold deposits through to development, taking advantage of our unique situation as a gold producer and developer working in world class mining jurisdictions."

~ Kevin Bullock, President and CEO, Anaconda Mining Inc.

The drill results from the Argyle Infill Program are currently being incorporated into an updated Mineral Resource Estimate and are being used for planning of the development and mining of the Argyle Deposit. Mercator Geological Services Limited has been engaged to provide an NI 43-101 Mineral Resource Update and Dassault Systèmes Canada Inc. has been engaged to provide pit shell optimization and preliminary open pit designs for the Argyle Deposit.

Argyle is a near-term development project and Anaconda anticipates making a final production decision with respect to Argyle in the third quarter of 2020.

Table 1: Highlighted composited assays from diamond drill holes AE-20-134 to 157

Hole ID1

From (m)

To (m)

Interval (m)2

Au (g/t)

AE-20-134

35.7

36.2

0.5

10.40

AE-20-135

22.6

29.6

7.0

1.19

AE-20-136

34.2

35.2

1.0

0.86

AE-20-137

31.0

31.6

0.6

4.56

AE-20-138

37.0

41.5

4.5

4.56

including

39.5

40.0

0.5

24.70

AE-20-140

19.5

23.5

4.0

5.26

and

26.5

27.1

0.6

1.59

AE-20-141

8.7

11.7

3.0

1.18

and

15.7

16.7

1.0

1.41

AE-20-142

11.0

12.0

1.0

0.79

and

14.0

17.0

3.0

1.32

and

25.2

26.2

1.0

3.14

AE-20-143

15.0

23.5

8.5

2.16

AE-20-144

10.8

11.8

1.0

1.19

AE-20-146

49.0

50.0

1.0

1.55

and

60.4

61.4

1.0

1.36

and

73.7

74.3

0.6

1.00

AE-20-147

57.5

58.5

1.0

1.54

and

67.5

68.4

1.1

8.71

AE-20-148

14.7

15.2

0.5

0.63

and

18.5

19.5

1.0

1.90

AE-20-150

66.0

67.0

1.0

2.79

AE-20-151

64.0

66.0

2.0

4.02

and

73.5

75.0

1.5

0.79

AE-20-156

35.0

36.0

1.0

2.20

AE-20-157

42.0

44.0

2.0

3.98

Footnotes:

1 – Diamond drill holes AE-20-139, 145, 149, 152-155 have no significant assays.

2 – Interval expressed as core length only; true thickness estimated to be 90-100% of interval length.

Table 2: Highlighted composited assays from percussion drill holes AEP-20-26 to 86

Hole ID3

From (m)

To (m)

Interval (m)4

Au (g/t)

AEP-20-26

15.54

16.45

0.91

2.88

AEP-20-31

8.23

9.14

0.91

0.69

AEP-20-36

4.57

6.40

1.83

0.99

AEP-20-37

4.57

6.40

1.83

1.89

AEP-20-38

7.32

10.98

3.66

1.36

AEP-20-42

9.14

10.97

1.83

0.99

AEP-20-43

8.23

9.14

0.91

1.02

AEP-20-45

8.23

10.06

1.83

1.99

AEP-20-46

7.32

10.98

3.66

1.43

AEP-20-47

9.14

10.05

0.91

2.52

AEP-20-48

1.83

9.15

7.32

1.87

including

7.32

8.23

0.91

6.34

AEP-20-49

11.89

16.46

4.57

2.15

AEP-20-50

10.97

15.54

4.57

6.62

AEP-20-51

8.23

9.14

0.91

2.64

AEP-20-52

6.40

10.97

4.57

3.14

AEP-20-53

8.23

12.80

4.57

2.07

AEP-20-54

3.66

8.23

4.57

1.34

AEP-20-56

9.14

10.97

1.83

4.73

AEP-20-57

0.91

1.82

0.91

1.54

and

3.66

4.57

0.91

3.23

AEP-20-58

1.83

5.49

3.66

1.68

AEP-20-60

20.12

21.03

0.91

2.27

AEP-20-61

0.91

1.82

0.91

0.91

and

3.66

6.40

2.74

1.94

AEP-20-67

0.91

2.74

1.83

2.40

AEP-20-69

10.06

10.97

0.91

0.97

AEP-20-70

17.37

18.28

0.91

1.83

AEP-20-71

1.83

2.74

0.91

1.92

AEP-20-76

0.91

2.74

1.83

0.74

AEP-20-78

7.32

16.46

9.14

4.48

including

9.14

10.05

0.91

16.60

AEP-20-79

6.40

9.14

2.74

2.42

AEP-20-80

8.23

10.06

1.83

1.01

AEP-20-81

10.97

11.88

0.91

0.86

Footnotes:

3 – Percussion drill holes AEP-20-27-30, 32-35, 39-41, 44, 55, 59, 62-66, 68, 72-75, and 77 have no significant assays.

4 – Interval expressed as core length only; true thickness estimated to be 90-100% of interval length.

About Argyle

The Argyle Deposit, located 4.5 kilometres east of the Pine Cove Mill adjacent to existing road networks, is defined over a strike length of 685 metres and to a down-dip extent of 225 metres and is open for expansion. The Argyle Deposit was subject to a detailed NI 43-101 Technical Report titled "NI 43-101 Technical Report, Mineral Resource and Mineral Reserve Update Point Rousse Project, Baie Verte, Newfoundland and Labrador, Canada" with an effective date of December 31, 2017. Since the December 2017 Resource, a total of 7,940 metres in 152 drill holes have been completed at Argyle.

Argyle Mineral Resource Estimate – Effective Date: December 31, 2017

Resource Category

Resource Cut-off Gold Grade

(g/t)

Tonnes

(Rounded)

Gold Grade (g/t)

(12 g/t Capping Factor)

Gold Ounces

(Rounded)

Indicated

0.5

543,000

2.19

38,300

Inferred

0.5

517,000

1.82

30,300

This news release has been reviewed and approved by Paul McNeill, P. Geo., VP Exploration with Anaconda Mining Inc., a "Qualified Person", under National Instrument 43-101 Standard for Disclosure for Mineral Projects.

Mineralized intervals referred to in this press release are reported as drill intersections and are apparent widths only. True widths are estimated to be approximately 90-100% of drill intervals.

All samples and the resultant assays and composites referred to in this release were collected using QA/QC protocols including the regular insertion of certified standards and blanks within each sample batch sent for analysis and completion of check assays of select samples. Diamond drill core and percussion samples were analyzed for Au at Eastern Analytical Ltd. in Springdale, NL ("Eastern"), using standard fire assay (30 g) pre-concentration and Atomic Absorption finish methods. Eastern is a fully accredited firm within the meaning of NI 43-101 for provision of this service.

Percussion drilling was conducted using a Sandvik percussion drill rig with a 4-inch bore. Dry cuttings returned from the drill were collected every 0.91 metres of drilling from a plastic pail using a scoop holding approximately 1-2 kg sample. Percussion cuttings include a variety of size fractions of pulverized rock. An analysis of 16 pairs of twinned diamond drill holes and percussion holes within 12 metres of each other showed a strong correlation between grade and width of the mineralized zone.

Diamond drilling at Argyle outlined within this press release, benefited from a JEA grant from the Department of Natural Resources, Government of Newfoundland and Labrador. Anaconda thanks the Government of Newfoundland and Labrador for this assistance.

ABOUT ANACONDA

Anaconda is a TSX and OTCQX-listed gold mining, development, and exploration company, focused in Atlantic Canada. The company operates mining and milling operations in the prolific Baie Verte Mining District of Newfoundland which includes the fully-permitted Pine Cove Mill, tailings facility and deep-water port, as well as ~11,000 hectares of highly prospective mineral lands including those adjacent to the past producing, high-grade Nugget Pond Mine at its Tilt Cove Gold Project. Anaconda is also developing the Goldboro Gold Project in Nova Scotia, a high-grade resource and the subject of an on-going feasibility study.

FORWARD-LOOKING STATEMENTS

This news release contains "forward-looking information" within the meaning of applicable Canadian and United States securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Anaconda to be materially different from those expressed or implied by such forward-looking information, including risks associated with the exploration, development and mining such as economic factors as they effect exploration, future commodity prices, changes in foreign exchange and interest rates, actual results of current production, development and exploration activities, government regulation, political or economic developments, environmental risks, permitting timelines, capital expenditures, operating or technical difficulties in connection with development activities, employee relations, the speculative nature of gold exploration and development, including the risks of diminishing quantities of grades of resources, contests over title to properties, and changes in project parameters as plans continue to be refined as well as those risk factors discussed in Anaconda's annual information form for the year ended December 31, 2019, available on www.sedar.com. Although Anaconda has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Anaconda does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

FOR ADDITIONAL INFORMATION CONTACT:

Anaconda Mining Inc.
Kevin Bullock
President and CEO
(647) 388-1842
kbullock@anacondamining.com

Reseau ProMarket Inc.
Dany Cenac Robert
Investor Relations
(514) 722-2276 x456
Dany.Cenac-Robert@ReseauProMarket.com

Anaconda Mining Inc.
Lynn Hammond
VP, Corporate Affairs
(709) 330-1260
lhammond@anacondamining.com

Exhibit A. A map showing the location of the Argyle Deposit along the eastern end of the Scrape Trend: a geological trend that is host to the Argyle Deposit, Stog'er Tight Mine, and Pine Cove Mine and Mill Complex, Point Rousse Project. For a higher resolution image, please click here. 

Exhibit B. A map showing the location of diamond and percussion drill holes completed during the Argyle Infill Program referenced in the press release with highlight assays. For a higher resolution image, please click here. 

SOURCE: Anaconda Mining Inc.

ReleaseID: 594276

KELOWNA, BC / ACCESSWIRE / June 18, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application to the U.S. National Institutes of Health (NIH) entitled "In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement." pursuant to their National Institute of Allergy and Infectious Diseases (NIAID) Funding Opportunity Announcement (FOA) RFA-AI-20-028 – Partnerships for Countermeasures against Select Pathogens.

This grant application is for funding to support Lexaria's second round of planned studies related to COVID-19 treatment possibilities.

The purposes of FOA RFA-AI-20-028 is to receive research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID emerging infectious diseases/pathogens of interest including COVID-19 caused by SARS-CoV-2 infection. The NIAID supports extramural research focused on understanding, controlling and preventing diseases caused by virtually all infectious agents. FOA RFA-AI-20-028 encourages research and development projects that advance identified lead candidate vaccine and therapeutic compounds with a view of significantly advancing these compounds toward clinical or field usefulness.

Lexaria's application included a detailed summary of its research plans to investigate the potential effectiveness of its patented DehydraTECH drug delivery platform technology in enabling improved safety and efficacy of certain poorly water soluble antiviral drugs against SARS-CoV-2 infected cells and animals. Lexaria has not publicly disclosed the identity of the antiviral drugs it plans to investigate in this program, but, it has made its selections from drug classes that have shown early promise in COVID-19 therapeutic utility from research recently conducted by other researchers in the field. Lexaria's application also provided the NIH/NIAID reviewers with an overview of Lexaria's preclinical and clinical findings to-date evidencing the ability of its DehydraTECH technology to improve the absorption and effectiveness of the range of other poorly water soluble bioactive drug compounds it has previously studied.

The Company cautions that, across all sectors, many research grant applications are not successfully granted and Lexaria cannot predict whether this NIH grant application will be successful or not.

On March 19, 2020 Lexaria announced plans to conduct a pilot safety and pharmacokinetic study in healthy human volunteers of certain DehydraTECH antiviral drug formulations in order to perform a preliminary evaluation of the extent of oral bioabsorption enhancement DehydraTECH can offer for antiviral drugs, where a study design and plan have been submitted for pending ethics board approval. If successful, this study together with the expanded efficacy modelling in SARS-CoV-2 infected cells and animals described herein are expected to produce a compelling data set for Lexaria to present to prospective pharmaceutical industry strategic partners consistent with its business model of commercializing its scientific advancements through third-party out-licensing arrangements.

Additionally, the Company also reports that its subsidiary Lexaria CanPharm ULC has successfully received a new license from Health Canada, issued in accordance with the Cannabis Act and Cannabis Regulations, that allows for expanded testing capabilities including sensory testing of cannabis oral products for taste, smell, and additional research and evaluation. The license is effective now and expires August 9, 2023. The Company expects that its expanded new evaluation capabilities will enable it to more quickly advance its technology for use in various product categories.

About the NIH and NIAID

The National Institutes of Health (NIH) and other agencies in the Department of Health and Human Services (DHHS) support development of countermeasures to protect the public from infectious diseases. In 2002, the NIH initiated development of strategic plans to counter threats presented by emerging infectious diseases. As a component of these plans, NIAID was assigned responsibility for research leading to and development of candidate countermeasures against a growing list of emerging pathogens. NIAID established the Partnerships program to support discovery, preclinical research, product development and eventual commercialization of candidate products that address specific pathogens/agents. This FOA reflects current priorities outlined in the NIAID Strategic Plan for Biodefense Research, the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan, the National Strategy for Combating Antibiotic-Resistant Bacteria (CARB), the National Action Plan for Combating Multi-drug Resistant Tuberculosis, the HHS 2010 Medical Countermeasure Review, and Homeland Security Presidential Directive 18: Medical Countermeasures against Weapons of Mass Destruction.

About Lexaria

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

www.lexariabioscience.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Chris Bunka, CEO
(250) 765-6424

Forward-Looking Statements

Statements in this release concerning Lexaria's future expectations and plans, including, without limitation, the use of proceeds from the offering, financial needs of the Company and potential uplisting onto a national stock exchange may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Lexaria believes that the expectations reflected in the forward-looking statements are reasonable, Lexaria cannot guarantee such outcomes. Lexaria may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Lexaria's most recent Annual Report on Form 10-K and Lexaria's other filings made with the SEC. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Lexaria's current plans, estimates, and beliefs. Lexaria cannot guarantee future results, events, levels of activity, performance or achievements. Lexaria does not undertake, and specifically declines, any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

ReleaseID: 594260

Repeated immunisation with PD01A is safe and well-tolerated over an extended time period
Active immunisation with PD01A resulted in a substantial aSyn-specific antibody response and memory effect
This antibody response was associated with a substantial reduction in CSF oligomeric aSyn protein
Results represent long-term data from a first-in-human study series using specific active immunotherapy (SAIT) AFFITOPE(R) PD01A

VIENNA, AUSTRIA / ACCESSWIRE / June 18, 2020 / AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology (https://doi.org/10.1016/S1474-4422(20)30136-8). The results of the long-term phase 1 trial series demonstrated that repeated immunisation with PD01A is safe and well-tolerated over an extended period of time. The data showed that active immunisation with PD01A leads to a positive antibody response specific for alpha-synuclein (aSyn), a protein that is believed to contribute to the pathogenesis of Parkinson's disease. Active immunisation also resulted in a substantial reduction (mean of 51%) in the levels of aSyn oligomers in the CSF of patients who received the high dose therapy, which is interpreted as a sign of in vivo target engagement.

Extensive evidences support the role of soluble aSyn oligomers as a causative factor in the development of Parkinson's disease and reducing the levels of aSyn oligomers could potentially have disease-modifying benefit in PD patients.

In the trial, the patients were randomised to receive four immunisations with two different doses of AFFiRiS' drug candidate and were followed for at least 3.5 years to assess the safety of the PD01A immunotherapeutic. In particular, this was the first study to assess the feasibility and safety of a specific active immunotherapy against aSyn.

The results of this phase 1 study demonstrated that immunisation with PD01A is safe when repeatedly administered and was well-tolerated over an extended time period. With the exception of expected local injection site reactions, most AEs were considered unrelated to study treatment. No patient discontinued due to treatment emergent adverse events. Immunisation resulted in a significant increase in IgG antibody against the immunizing AFFITOPE(R) PD01 peptide already after three priming injections with a maximum titre being achieved at Week 12. This led to a specific humoral immune response against the aSyn target epitope. Moreover, the priming immunisations resulted in a substantial memory effect for the aSyn target epitope as evidenced by the reactivation and augmentation of the antibody response following booster immunisations. This resulted in the persistence of the immune response until study end.

Although the study was not designed and not powered to evaluate clinical efficacy, clinical signals of efficacy were observed. In particular, MDS-UPDRS motor scores were generally stable across the study series, in contrast to published data which reports a worsening in MDS-UPDRS scores in a similar patient population.

"The PD01A safety profile and the substantial sustained aSyn antibody response targeting both the toxic oligomeric and fibrillar form of aSyn, which are believed to contribute to the pathology of PD, may offer a promising strategy for long-term management of PD, addressing an urgent medical need," said Dieter Volc M.D., principal investigator of the study series and Head of the Parkinson Center at the Privatklinik Confraternitaet, Vienna.

"The encouraging results, including signals for clinical efficacy, warrant the further development of our drug for the treatment of PD in a phase 2 clinical trial," commented Noel Barrett, Ph.D., AFFiRiS' Chief Executive Officer. "Potentially, specific active immunisation approaches such as with PD01A might overcome the limitations of passive antibody infusion approaches for PD, caused by their short in vivo half-lives, and circumvent frequent and high treatment costs by stimulating a self-produced, long-lasting immune reaction."

The data published in The Lancet Neurology is the first report of an active anti-aSyn immunotherapy associated with reduction of CSF aSyn oligomers in PD patients and points to the possible development of this protein as a potential biomarker for disease progression.

The phase 1 trial was supported by The Michael J. Fox Foundation for Parkinson's Research. A phase 2 trial in early-stage Parkinson's disease patients is in preparation and expected to start in the second half of 2020, depending on the emerging COVID-19 situation.

About the phase 1 clinical trial study:

The study was a patient-blinded, single-centre, randomised, first-in-human study followed by three consecutive extensions. 24 Parkinson's disease patients were randomised to receive four immunisations with either 15μg or 75μg PD01A and were followed for at least 3.5 years. For the first booster injection, patients were re-randomised to receive PD01A doses of 15μg or 75μg. All patients received a second booster injection of 75μg. The primary objective was to assess the safety of the PD01A immunotherapeutic. These studies were registered at EudraCT (2011-002650-31, 2013-001774-20, 2014-002489-54 and 2015-004854-16).

About AFFITOPE(R) PD01:

AFFITOPE(R) PD01 is AFFiRiS' novel immunotherapy candidate for the treatment of early-stage Parkinson's disease patients. PD01 is a synthetically produced alpha-synuclein (aSyn)-mimicking peptide-based specific active immunotherapy (SAIT), identified by AFFiRiS' AFFITOME(R) technology, that targets the protein aSyn. This protein has been identified as playing a key role in the onset and progression of Parkinson's disease.

About Parkinson's disease:

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and the most common neurodegenerative movement disease. It affects approximately 1% of the population above the age of 60, about 7-10 million people worldwide. PD is a chronic progressive disorder, defined by a combination of motoric and non-motoric syndromes. The hallmark of the disease is a substantial loss of dopaminergic neurons in the brain accompanied by accumulations of filamentous protein inclusions predominantly composed of alpha Synuclein (aSyn). Evidence suggests that the misfolding of the aSyn protein causes inflammation, synaptic dysfunction and finally neuronal cell death. Current therapies target symptoms but fail to modify the underlying neurodegeneration. In addition, these therapies result in varying degrees of side effects, and their beneficial effects diminish over time.

About AFFiRiS AG:

AFFiRiS is a clinical-stage biotechnology company located in Vienna, Austria, with a vision of using the immune system to identify and target human proteins central to the development and progression of neurodegenerative diseases, based on its proprietary patented AFFITOME(R) technology. The Company's ultimate goal is to improve the lives of patients suffering from these diseases by providing disease-modifying specific active immunotherapies (SAIT). With its lead candidate AFFITOPE(R) PD01, AFFiRiS is the leader in active immunotherapies for Parkinson's disease. AFFiRiS' programs against multiple system atrophy, dementia with Lewy bodies, and chorea Huntington are in pre-clinical development.

For further information, please visit www.affiris.com and follow us on LinkedIn and Twitter.

Contact AFFiRiS AG:
Dr. Cornelia Kutzer
E cornelia.kutzer@affiris.com
W www.affiris.com

Media contact:
MC Services AG
Julia Hofmann
P +49 89 210228 0
E affiris@mc-services.eu

About SAIT:
https://affiris.com/approach/#overview-of-sait

About neurodegenerative diseases:
https://affiris.com/neurodegenerative-diseases

SOURCE: AFFiRiS AG via EQS Newswire

ReleaseID: 594346

LUGANO, SWITZERLAND / ACCESSWIRE / June 18, 2020 / One of Jelurida's flagship products, the Ardor child chain Ignis, will be utilized by a new research project aiming to facilitate secure communication between Austrian authorities, institutions and citizens. Jelurida will participate as a key partner and provide consultancy for the QualiSig project.

Launched by Austrian trust service provider (A-Trust) in partnership with several organizations including the Donau-Universität Krems, QualiSig's goal is to ensure secure communication channels for data exchange between citizens, government agencies, and institutions commissioned by authorities in times of crisis.

With COVID-related communications entailing major data protection concerns, QualiSig was recently awarded a €60,000 grant from the Austrian Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation, and Technology and the Federal Ministry for Digital and Economic Affairs after responding to the Corona Emergency Call of the Research Promotion Agency (FFG) for COVID-19 prevention.

QualiSig depends on transparent, encrypted communications with testing personnel, and secure and decentralized storage of data. Data control will be the sole responsibility of citizens, with no special computer skills required.

"The mobile phone signature, with around 1.5 million users, is a widely used tool and has stood for highly secure authentication in the digital world for ten years," said Michael Butz, CEO of A-Trust. "With the QualiSig project, we would like to provide people living in Austria with the necessary security for secure and traceable communication in these difficult times."

The research proposal was written by Thomas Wernbacher and Alexander Pfeiffer of Donau-Universität Krems, and the combination of digital qualified signatures such as the "A-Trust Handy-Signature" and Ardor's Ignis child chain is based on Pfeiffer's current research.

"This project will combine qualified digital signatures based on compliant digital citizenship solutions with blockchain technology having the best of both worlds – government-approved authentication combined with a unique decentralized and encrypted data storage." said Kristina Kalcheva, co-founder of Jelurida.

QualiSig was one of several projects to receive funding after the Austrian Research Promotion Agency's Corona Emergency Call, with 26 million euros made available.

Use case: Health

The secure digital folder for health status verification takes into account the highest possible level of privacy for citizens and all related institutions and services. In addition, digitally signed and verified news updates can be displayed here, helping to combat the spread of fake news.

About Jelurida

Founded in Switzerland in 2017, Jelurida is a software company that develops and maintains the Ardor and Nxt blockchains. Now a multinational organization with offices on three continents, Jelurida is focused on helping enterprises capitalize on the benefits of blockchain through making it easier to deploy applications connected to the open Ardor and Nxt networks.

For more information please visit: www.jelurida.com

About A-Trust

A-Trust GmbH is an Austrian company that offers services for secure communication in the digital and mobile world. The focus of its diverse services is on confidentiality, integrity, and convenience as well as the creation of secure digital signatures. The company is a qualified trusted service provider according to eIDAS regulation. A-Trust, Gesellschaft für Sicherheitssysteme im elektronischen Datenverkehr, is subject to regular controls by the Rundfunk und Telekom Regulierungs-GmbH.

Fore more information please visit: https://www.a-trust.at/

About Donau-Universität Krems

Donau-Universität Krems is the leading public university for continuing education in Europe. With its expertise in teaching and research, it works to overcome societal challenges. The Centre for Applied Game Studies and the Department for E-Governance are both involved in the QualiSig project.

More information on the Corona Emergency Call and QualiSig: https://www.ffg.at/

Contact:

Dan Edelstein
pr@marketacross.com
+972-545-464-238

SOURCE: Jelurida

ReleaseID: 594205